Elsevier



Pre-accept checklist – non-clinical trial

General

□ Please clearly indicate funding and other non-financial support and the role of funders at end of Methods section.

□ We discourage priority claims such as “first” and “novel”, please rephrase any instances in the text.

□ Define all abbreviations.

□ Please give actual numbers (numerator and denominator) together with percentages.

□ All abstracts and references “in press” should be updated with DOIs or page numbers as appropriate. For papers listed in references that are “in press” we need to see a galley proof and/or letter from the publisher stating that it is “in press” as well as (where known) the full expected citation (i.e., publication date/volume/issue etc.). References that are “submitted” should be removed and citations in the text replaced with “(unpublished data; authors)”.

□ Avoid slashes (except ratios).

□ Use approved gene names. Italicize (approved gene names only) and format appropriately (e.g. all caps for human genes, first letter cap for mouse genes – see or ).

□ Please carefully follow the linked guidelines of reporting standards if your study falls within one the following categories, and fill in and return the checklist(s) where applicable:

|Animal preclinical studies |ARRIVE |

|Observational cohort and case-control studies |STROBE |

|Meta-analyses of observational studies |MOOSE |

|Systematic reviews and meta-analyses |PRISMA |

|Genetic association studies |STREGA |

|Genetic risk prediction studies |GRIPS |

|Diagnostic tests |STARD |

|Prognostic markers |REMARK |

|Biospecimens |BRISQ |

|Microarrays |MIAME |

For more information on reporting standards, please visit:

Title

□ Please avoid abbreviations in title. Please either define functionally (e.g., “the influenza viral HA protein”) or spell out (“influenza viral hemagglutinin”).

Highlights

□ Please provide 2–3 sentences in bulleted format, summarizing the key findings in your paper.

□ Each sentence (bullet) should be ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download